Mario Nuvolone

List of Publications by Year
in descending order

76 papers	3,033 citations	236925 25 h-index	168389 53 g-index
85 all docs	85 docs citations	85 times ranked	3674 citing authors

#	Article	IF	Citations
1	Proteaseâ€sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation. FEBS Journal, 2022, 289, 494-506.	4.7	25
2	Glial activation in prion diseases is selectively triggered by neuronal PrP^{Sc}. Brain Pathology, 2022, 32, e13056.	4.1	13
3	An N-glycosylation hotspot in immunoglobulin Îº light chains is associated with AL amyloidosis. Leukemia, 2022, 36, 2076-2085.	7.2	10
4	Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions. Communications Biology, 2022, 5, .	4.4	1
5	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. Blood Cancer Journal, 2021, 11, 34.	6.2	39
6	Scaling analysis reveals the mechanism and rates of prion replication in vivo. Nature Structural and Molecular Biology, 2021, 28, 365-372.	8.2	22
7	A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis. Expert Opinion on Drug Safety, 2021, 20, 411-426.	2.4	2
8	Tau Exon 10 Inclusion by PrPC through Downregulating GSK3Î² Activity. International Journal of Molecular Sciences, 2021, 22, 5370.	4.1	2
9	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood, 2021, 138, 1583-1589.	1.4	11
10	Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells. Biomedicines, 2021, 9, 1523.	3.2	0
11	The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis. Cell Reports, 2020, 32, 108162.	6.4	24
12	Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses. Frontiers in Pharmacology, 2020, 11, 1024.	3.5	25
13	Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside. Expert Review of Hematology, 2020, 13, 1003-1015.	2.2	5
14	Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis. Journal of Biological Chemistry, 2020, 295, 16572-16584.	3.4	32
15	Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy. Blood Cancer Journal, 2020, 10, 90.	6.2	15
16	Redirecting proteoxicity. Leukemia, 2020, 34, 3109-3110.	7.2	0
17	Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Advances, 2020, 4, 4175-4179.	5.2	24
18	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. Blood, 2020, 135, 293-296.	1.4	27

#	Article	IF	Citations
19	Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 231-236.	3.0	20
20	Genome-wide transcriptomics identifies an early preclinical signature of prion infection. PLoS Pathogens, 2020, 16, e1008653.	4.7	40
21	Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 168-173.	3.0	6
22	High rate of profound clonal and renal responses with daratumumab treatment in heavily preâ€treated patients with <scp>light chain (AL)</scp> amyloidosis and high bone marrow plasma cell infiltrate. American Journal of Hematology, 2020, 95, 900-905.	4.1	29
23	Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Advances, 2020, 4, 1321-1324.	5.2	27
24	Genome-wide transcriptomics identifies an early preclinical signature of prion infection. , 2020, 16, e1008653.		0
25	Genome-wide transcriptomics identifies an early preclinical signature of prion infection. , 2020, 16, e1008653.		0
26	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	1.4	5
27	New Insights Into a Multifaceted Disease. Mayo Clinic Proceedings, 2019, 94, 388-390.	3.0	0
28	ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. Analytical Chemistry, 2019, 91, 2894-2900.	6.5	26
29	Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice. Kidney International, 2019, 95, 258-260.	5.2	5
30	The Quest for Indicators of Profound Hematologic Response in AL Amyloidosis: Complete Response Remains the Optimal Goal of Therapy. Blood, 2019, 134, 1901-1901.	1.4	2
31	Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier. PLoS Pathogens, 2018, 14, e1007424.	4.7	9
32	Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. Scientific Reports, 2018, 8, 14600.	3.3	45
33	Management of the elderly patient with AL amyloidosis. European Journal of Internal Medicine, 2018, 58, 48-56.	2.2	23
34	Systemic amyloidosis: novel therapies and role of biomarkers. Nephrology Dialysis Transplantation, 2017, 32, gfw305.	0.7	49
35	Regulated expression of amyloidogenic immunoglobulin light chains in mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 52-53.	3.0	4
36	Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 66-67.	3.0	3

#	Article	IF	Citations
37	Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 54-55.	3.0	3
38	Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 68-69.	3.0	6
39	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	3.0	9
40	Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 60-61.	3.0	2
41	Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 64-65.	3.0	6
42	Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1734-1743.	2.3	33
43	Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Expert Opinion on Therapeutic Targets, 2017, 21, 1095-1110.	3.4	19
44	Extended characterization of the novel co-isogenic C57BL/6J Prnpâˆ’/âˆ’ mouse line. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 36-37.	3.0	5
45	Cystatin F is a biomarker of prion pathogenesis in mice. PLoS ONE, 2017, 12, e0171923.	2.5	20
46	Prion pathogenesis is unaltered in the absence of SIRPÎ±-mediated "don't-eat-me" signaling. PLoS ONE, 2017, 12, e0177876.	2.5	7
47	The Priority position paper: Protecting Europe's food chain from prions. Prion, 2016, 10, 165-181.	1.8	13
48	A neuroprotective role for microglia in prion diseases. Journal of Experimental Medicine, 2016, 213, 1047-1059.	8.5	127
49	Strictly co-isogenic C57BL/6J-Prnpâˆ’/âˆ’ mice: A rigorous resource for prion science. Journal of Experimental Medicine, 2016, 213, 313-327.	8.5	98
50	The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. Nature, 2016, 536, 464-468.	27.8	169
51	Expanding the spectrum of systemic amyloid diseases: aÂnew hint from the kidney. Kidney International, 2016, 90, 479-481.	5.2	10
52	A neuroprotective role for microglia in prion diseases. Journal of Cell Biology, 2016, 213, 2134OIA109.	5.2	1
53	Strictly co-isogenic C57BL/6J-Prnpâˆ’/âˆ’mice: A rigorous resource for prion science. Journal of Cell Biology, 2016, 212, 2126OIA42.	5.2	0
54	Structure-based drug design identifies polythiophenes as antiprion compounds. Science Translational Medicine, 2015, 7, 299ra123.	12.4	130

#	Article	IF	Citations
55	Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice. Journal of Biological Chemistry, 2015, 290, 26350.	3.4	5
56	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. Current Clinical Pathology, 2015, , 9-29.	0.0	3
57	Prion Pathogenesis in the Absence of NLRP3/ASC Inflammasomes. PLoS ONE, 2015, 10, e0117208.	2.5	37
58	The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis. PLoS Pathogens, 2014, 10, e1004531.	4.7	57
59	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113
60	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
61	The immunobiology of prion diseases. Nature Reviews Immunology, 2013, 13, 888-902.	22.7	127
62	SIRPÎ± polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells. Journal of Experimental Medicine, 2013, 210, 2539-2552.	8.5	67
63	Efficient Amyloid A Clearance in the Absence of Immunoglobulins and Complement Factors. American Journal of Pathology, 2013, 182, 1297-1307.	3.8	10
64	A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica, 2013, 98, 433-436.	3.5	65
65	The Complex PrP^c-Fyn Couples Human Oligomeric AÎ² with Pathological Tau Changes in Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16857-16871.	3.6	254
66	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	1.8	78
67	Transthyretin-associated Familial Amyloid Polyneuropathy - Current and Emerging Therapies. European Neurological Review, 2012, 7, 14.	0.5	2
68	Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis. , 2012, , 9-29.		0
69	Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 87-90.	3.0	17
70	Prion protein and AÎ²â€related synaptic toxicity impairment. EMBO Molecular Medicine, 2010, 2, 306-314.	6.9	234
71	Efficient Generation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood in Stroma-Free Liquid Culture. PLoS ONE, 2010, 5, e15689.	2.5	23
72	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	3.2	225

#	Article	IF	Citations
73	Cells and prions: A license to replicate. FEBS Letters, 2009, 583, 2674-2684.	2.8	24
74	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
75	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	1.4	182
76	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62